Novartis shares owned by Cascade Investment Advisors
Quarter-by-quarter ownership of Novartis (NVS) shares owned by Cascade Investment Advisors
from 13F filings
Historical chart of Cascade Investment Advisors investment in Novartis
Tip: Access up to 7 years of quarterly data
All positions including Novartis held by Cascade Investment Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csvQuarterly reported holdings in Novartis by Cascade Investment Advisors
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2025-09-30 | $2.7M | 21k | 128.24 |
| 2025-06-30 | $2.6M | 22k | 121.01 |
| 2025-03-31 | $2.5M | 22k | 111.48 |
| 2024-12-31 | $2.2M | 23k | 97.31 |
| 2024-09-30 | $2.6M | 22k | 115.02 |
| 2024-06-30 | $2.4M | 23k | 106.46 |
| 2024-03-31 | $2.2M | 23k | 96.73 |
| 2023-12-31 | $2.2M | 22k | 100.97 |
| 2023-09-30 | $2.3M | 22k | 101.86 |
| 2023-06-30 | $2.3M | 23k | 100.91 |
| 2023-03-31 | $2.1M | 23k | 92.00 |
| 2022-12-31 | $2.1M | 23k | 90.72 |
| 2022-09-30 | $1.9M | 23k | 81.14 |
| 2022-06-30 | $1.9M | 23k | 84.53 |
| 2022-03-31 | $2.0M | 23k | 87.75 |
| 2021-12-31 | $2.1M | 23k | 87.47 |
| 2021-09-30 | $1.8M | 23k | 81.78 |
| 2021-06-30 | $2.0M | 22k | 91.24 |
| 2021-03-31 | $1.8M | 22k | 85.48 |
| 2020-12-31 | $2.0M | 21k | 94.43 |
| 2020-09-30 | $1.8M | 21k | 86.96 |
| 2020-06-30 | $1.8M | 21k | 87.34 |
| 2020-03-31 | $1.7M | 21k | 82.45 |
| 2019-12-31 | $2.0M | 21k | 94.69 |
| 2019-09-30 | $2.0M | 23k | 86.90 |
| 2019-06-30 | $2.0M | 22k | 91.31 |
| 2019-03-31 | $2.1M | 22k | 96.14 |
| 2018-12-31 | $1.9M | 22k | 85.81 |
| 2018-09-30 | $1.9M | 22k | 86.16 |
| 2018-06-30 | $1.7M | 23k | 75.54 |
| 2018-03-31 | $2.1M | 26k | 80.85 |
| 2017-12-31 | $2.2M | 26k | 83.96 |
| 2017-09-30 | $2.2M | 26k | 85.85 |
| 2017-06-30 | $2.1M | 26k | 83.47 |
| 2017-03-31 | $1.9M | 26k | 74.27 |
| 2016-12-31 | $1.9M | 26k | 72.84 |
| 2016-06-30 | $1.9M | 23k | 82.51 |
More positions owned by Cascade Investment Advisors
View all positions for Cascade Investment Advisors